Drug intelligence / Profile preview

TPC-036

Development stage: Preclinical
Lead developer: Tetra Pharm Technologies
Modality: Small Molecules

Overview

TPC-036 is an investigational drug candidate being developed by Tetra Pharm Technologies for the treatment of obesity. It is currently in the discovery to preclinical stage of development. Tetra Pharm Technologies specializes in the research and development of pharmaceutical products that target the endocannabinoid system (ECS), a complex cell-signaling system involved in regulating a variety of functions including metabolism and appetite. TPC-036 is part of the company's metabolic disease pipeline, which also includes candidates for insulin resistance and MASH/NASH.

Beyond the preview

Go deeper on TPC-036.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TPC-036.

Explore the full profile